



Implanet strengthens intellectual property protection of JAZZ through 2032 by obtaining a key United States patent

Patent is the latest addition to a portfolio of 20 patents protecting the JAZZ technological platform and represents a major firewall for Implanet in an American market that places a strong emphasis on intellectual property rights

Bordeaux, Boston, August 30, 2016 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that the US Patent and Trademark Office (USPTO) has granted Implanet a patent for the JAZZ® technological platform in the United States.

The JAZZ technological platform's intellectual protection now covers the braided implant and its tensioning system, the principal element of its instrumentation. Implanet now possesses intellectual property architecture covering the specificities of its JAZZ® platform in the countries defined as priority markets during the Company's IPO, i.e. the United States, Europe, China, Japan, Australia and South Africa. Implanet is now the only spine surgery player, apart from Zimmer Spine, to have patents for a spinal fixation technical solution enabling the braid's tension and the implant's position on the rod to be locked with a single screw.

Régis Le Couedic, Implanet's Product Development & Manufacturing Director, says: *"Being granted this patent in the world's most advanced medical market represents major recognition by the authorities of the pre-eminence and innovative nature of our spine implant technology. This patent is a guarantee of JAZZ's future in the United States, where surgeons demand increasingly innovative medical technologies. Our band implant and its tensioning instrument are now protected in our priority markets, and we will continue to extend our field of protection to other innovations currently in late-stage development."*

Ludovic Lastennet, CEO of Implanet, adds: *"Obtaining this patent is a major value-creation milestone for Implanet. This protection creates a solid barrier to potential competitors in an American market that places a strong emphasis on intellectual property rights. Thanks to this protection, we have total confidence in our continued acceleration in the United States."*

Next financial press release: results for the 1st half of 2016, on September 23, 2016

Upcoming congresses and conferences:

SRS in Prague, September 21 to 24, 2016

ICCC in São Paulo, September 30 to October 1, 2016

EUROSPINE in Berlin, October 6 to 8, 2016

NASS in Boston, October 26 to 28, 2016

SOFCOT in Paris, November 8 to 11, 2016

Reminder of recent press releases:

Green light for a new implant: JAZZ Lock®, April 2016

Q1 2016 revenues: Strong increase in U.S. JAZZ sales: +106%, April 2016

Launch of the new JAZZ Claw® implant, May 2016

Q2 2016 record revenue of €2.1 million with Spine sales growing by +68%, July 2016

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

IMPLANET

Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com

NewCap

Investor Relations
Florent Alba
Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu

NewCap

Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu

AlphaBronze

US-Investor Relations
Pascal Nigen
Tel.: +1 917 385 21 60
implanet@alphabronze.net